Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 27, 2008

View Archived Issues

Sangamo's new zinc finger protein transcription factor neuroprotective in spinal injury model

TMC-435350 well tolerated, with dose-dependent anti-HCV activity in phase II study

Med Discovery and Laborium Biopharma sign bioprocess development partnership

Idera and Merck & Co. extend research collaboration for Toll-like receptor agonists

Novel PGE2 receptor modulators emerge from Astellas R&D

New immunomodulatory agents disclosed in recent Novartis patent

Recent GSK patents disclose novel agents for tuberculosis

FDA accepts for review Labopharm's trazodone NDA for major depressive disorder

Phylogica to acquire all outstanding shares in subsidiary Dynamic Microbials

FDA extends review of Somaxon's NDA for insomnia drug Silenor by 3 months

Emisphere reports results from Novartis Pharma study of PTH-134 using Eligen technology

Covidien licenses worldwide rights to DepoMed's AcuForm drug delivery technology

King Pharmaceuticals signs definitive merger agreement with Alpharma

Transgene's TG-1042 meets primary endpoint in CBCL phase II trial

Recordati files MAA in Europe for silodosin for benign prostatic hyperplasia

Schering-Plough reports top-line results for Saphris in schizophrenia

Genzyme files sNDA for Clolar in adult myeloid leukemia

Preladenant meets primary endpoint in phase II dose-finding trial in PD

Advisory committee recommends FDA approval of febuxostat for gout

Aldose reductase inhibition lowers urinary albumin excretion in type 1 diabetes

Vascugel safe in phase I/II study in patients with arteriovenous access

Severity reduction of EAE with new sPLA2 inhibitor peptide

Lilly completes acquisition of ImClone Systems

Cephalon and ImmuPharma sign USD 15 million option agreement for Lupuzor for SLE

Phase I study data on ITMN-191 presented, ITMN-5489 introduced

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...